Niels Svenstrup
Corporate Officer/Principal en PEPGEN INC. .
Fortuna: 147 000 $ al 31/03/2024
Perfil
Niels Svenstrup is currently the SVP-Chemistry, Manufacturing & Control at PepGen Inc. Prior to this, he was the Senior Vice President-Development at Cydan II, Inc. from 2017 to 2021.
He was also the Director-CMC at Ascendis Pharma A from 2015 to 2017 and the Head-Medicinal Chemistry Department at H.
Lundbeck A from 2008 to 2015.
Dr. Svenstrup holds a graduate and doctorate degree from the University of Southern Denmark.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
PEPGEN INC.
0.03% | 01/03/2024 | 10 000 ( 0.03% ) | 147 000 $ | 31/03/2024 |
Cargos activos de Niels Svenstrup
| Empresas | Cargo | Inicio |
|---|---|---|
| PEPGEN INC. | Corporate Officer/Principal | 01/04/2021 |
Antiguos cargos conocidos de Niels Svenstrup.
| Empresas | Cargo | Fin |
|---|---|---|
Cydan II, Inc.
 Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/04/2021 |
| ASCENDIS PHARMA A/S | Corporate Officer/Principal | 01/07/2017 |
| H. LUNDBECK A/S | Corporate Officer/Principal | 01/11/2015 |
Formación de Niels Svenstrup.
| University of Southern Denmark | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| H. LUNDBECK A/S | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| PEPGEN INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Cydan II, Inc.
Cydan II, Inc. Pharmaceuticals: GenericHealth Technology Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Niels Svenstrup
